Table 3. BI after 30 days of treatment among the aspirin, rt-PA, rPA, rt-PA + aspirin, and rPA + aspirin groups (n, %).
| Groups | 61–99 points | 41–60 points | ≤40 points |
|---|---|---|---|
| Aspirin group (n = 117) | 55 (47.01) | 42 (35.90) | 20 (17.09) |
| rt-PA group (n = 121) | 65 (53.72) | 39 (32.23) | 17 (14.05) |
| rPA group (n = 123) | 64 (52.03) | 40 (32.52) | 19 (15.45) |
| rt-PA + aspirin group (n = 126) | 85 (67.46)1 | 32 (25.4) | 9 (7.14) |
| rPA + aspirin group (n = 124) | 83 (66.94)1,2 | 31 (25.0) | 10 (8.06) |
Notes: rPA, Reteplase; rt-PA, Alteplase.1P < 0.05, compared with the aspirin, rt-PA, and rPA groups at the same scoring interval. 2P > 0.05, compared with the rt-PA + aspirin group at the same scoring interval.